<DOC>
	<DOC>NCT01119937</DOC>
	<brief_summary>This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD) .</brief_summary>
	<brief_title>Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients with moderate to severe stable COPD (Stage II or Stage III) according to the Gold Guideline 2008. Current or exsmokers who have a smoking history of at least 10 pack years. Patients with a postbronchodilator FEV1 â‰¥30% and &lt; 80% of the predicted normal, and postbronchodilator FEV1/FVC &lt; 0.7 at Visit 2 (day 7) Pregnant women or nursing mothers or women of childbearing potential not using an acceptable method of contraception Patients requiring long term oxygen therapy Patients who have had a lower respiratory tract infection within 6 weeks prior to Visit 1 Patients with concomitant pulmonary disease Patients with a history of asthma Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Patients with a known history and diagnosis of alpha1 antitrypsin deficiency Patients in the active phase of a supervised pulmonary rehabilitation program Patients contraindicated for tiotropium or ipratropium treatment or who have shown an untoward reaction to inhaled anticholinergic agents Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>NVA237</keyword>
</DOC>